Serum cystatin C and tubular urinary enzymes as biomarkers of renal dysfunction in type 2 diabetes mellitus

Clinical Medicine Insights: Endocrinology and Diabetes

Volumn 6, Issue , 2013, Pages 7-13

  Assal, Heba S ^a   Tawfeek, Salwa ^a   Rasheed, Enas A ^a   El Lebedy, Dalia ^a   Thabet, Eman H ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Cystatin C; Diabetic nephropathy; N acetyl beta d glucosaminidase; Neutrophil gelatinase associated lipocalin

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; N ACETYL BETA GLUCOSAMINIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; KIDNEY INJURY; MACROALBUMINURIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84881039934     PISSN: 11795514     EISSN: 11795514     Source Type: Journal    
DOI: 10.4137/CMED.S12633     Document Type: Article

References (37)

1. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis. 2005;12:177-186.
2. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17(11):2974-2984.
3. Morii T, Fujita H, Narita T, et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complicat. 2003;17(1):11-15.
4. Piwowar A, Knapik-Kordecka M, Fus I, Warwas M. Urinary activities of cathepsin B, N-acetyl-beta-D-glucosaminidase, and albuminuria in patients with type 2 diabetes mellitus. Med Sci Monit. 2006;12(5):CR210-CR214.
5. Mohammadi-Karakani A, Asgharzadeh-Haghighi S, Ghazi-Khansari M, Hosseini R. Determination of urinary enzymes as a marker of early renal damage in diabetic patients. J Clin Lab Anal. 2007;21(6):413-417.
6. Phillips AO. The role of renal proximal tubular cells in diabetic nephropathy. Curr Diab Rep. 2003;3:491-496.
7. Hirsch R, Dent C, Pfriem H, et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol. 2007;22(12): 2089-2095.
8. Mishra J, Dent C, Tarabishi R, et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005;365:1231-1238.
9. Trachtman H, Christen E, Cnaan A, et al; Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Urinary neutrophil gelatinase-associated lipocalcin in D + HUS: a novel marker of renal injury. Pediatr Nephrol. 2006;21(7):989-994.
10. Mitsnefes MM, Kathman TS, Mishra J, et al. Serum neutrophil gelatinase-associated lipocalin as a marker of renal function in children with chronic kidney disease. Pediatr Nephrol. 2007;22(1):101-108.
11. Suzuki M, Wiers KM, Klein-Gitelman MS, et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis. Pediatr Nephrol. 2008;23(3):403-412.
12. Ding H, He Y, Li K, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol. 2007;123(2):227-234.
13. Bolignano D, Coppolino G, Campo S, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is associated with severity of renal disease in proteinuric patients. Nephrol Dial Transplant. 2008;23(1):414-416.
14. Bolignano D, Coppolino G, Campo S, et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol. 2007;27:373-378.
15. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care. 2010;33(10):2184-2189.
16. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-S266.
17. Varley H, Gowenlock AH, Bell M. Practical Clinical Biochemistry, Vol. I, 5th ed. Great Britian; Willian Heinmann Medical Books Ltd; 1980:388-400.
18. Pecoraro RE, Graf RJ, Halter JB, Beiter H, Porte D. Comparison of a colorimetric assay for glycosylated hemoglobin with ion-exchange chromatography. Diabetes. 1979;28(12):1120-1125.
19. Comper WD, Osicka TM, Jerums G. High prevalence of immuno-unreactive intact albumin in urine of diabetic patients. Am J Kidney Dis. 2003;41(2): 336-342.
20. Hossain MA, Emara M, El Moselhi H, Shoker A. Comparing measures of cystatin C in human sera by three methods. Am J Nephrol. 2009;29(5): 381-391.
21. Vaidya VS, Waikar SS, Ferguson MA, et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci. 2008;1(3):200-208.
22. Uslu S, Efe B, Alataş O, et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J Nephrol. 2005;18(5):559-567.
23. Choe JY, Park SH, Kim SK. Serum cystatin C is a potential endogenous marker for the estimation of renal function in male gout patients with renal impairment. J Korean Med Sci. 2010;25(1):42-48.
24. Rigalleau V, Beauvieux MC, Le Moigne F, et al. Cystatin C improves the diagnosis and stratification of chronic kidney disease, and the estimation of glomerular filtration rate in diabetes. Diabetes Metab. 2008;34(5):482-489.
25. Shlipak MG. Cystatin C as a marker of glomerular filtration rate in chronic kidney disease: influence of body composition. Nat Clin Pract Nephrol. 2007;3(4):188-189.
26. Nauta FL, Boertien WE, Bakker SJ, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care. 2011;34(4): 975-981.
27. Ogawa Y, Goto T, Tamasawa N, et al. Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy. Diabetes Res Clin Pract. 2008;79(2):357-361.
28. Naicker S. Biomarkers of renal disease. South Afr J Anaesth Analg. 2011;17: 118-119.
29. Bolignano D, Lacquaniti A, Coppolino G, et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009;32(2):91-98.
30. Jiao LY, Guo Q, Song Z, Lucy G. Diagnostic value of urinary neutrophil gelatinase associated lipocalin and serum cystatin C on diabetic Nephropathy, Journal of Xinxiang Medical College. 2011;5:21.
31. Nielsen SE, Schjoedt KJ, Astrup AS, et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med. 2010;27(10):1144-1150.
32. Tong JR, He F, Luo Z. Value of serum NGAL and Cystatin C in diagnosing early phase of diabetic nephropathy. Chinese General Practice. 2010;8:2009.
33. Basturk T, Altuntaş Y, Kurklu A, Aydin L, Eren N, Unsal A. Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination. Ren Fail. 2006;28(2):125-128.
34. Manal MA, El-Naggar S, El-Aasar A, Barakat Khlood I. Bioremediation of crystal violet using air bubble bioreactor packed with Pseudomonas aeruginosa. Water Res. 2005;39(20):5045-5054.
35. Yang YH, He XJ, Chen SR, Wang L, Li EM, Xu LY. Changes of serum and urine neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. Endocrine. 2009;36(1):45-51.
36. Vlastimir V, Stojimirović R. Damage of tubule cells in diabetic nephropathy type 2: urinary N-acetyl-beta-D-glucosaminidasis and gamma-glutamil-transferase. Vojnosanit Pregl. 2007;64(2):123-127.
37. Vaidya VS, Niewczas MA, Ficociello LH, et al. Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int. 2011;79(4):464-470.